Preview

Остеопороз и остеопатии

Расширенный поиск

КАЛЬЦИМИМЕТИКИ - НОВЫЙ КЛАСС ПРЕПАРАТОВ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПАРАТИРЕОЗА

https://doi.org/10.14341/osteo2008229-37

Список литературы

1. Amann K., Tornig J., Kugel B., Gross M.L., Tyralla K., El-Shakmak A., Szabo A., Ritz E. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63: 1296-1301, 2003

2. Amann K., Ritz E., Wiest G., Klaus G., Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4: 1814-1819, 1994

3. Amann K., Tornig J., Flechtenmacher C., Nabokov A., Mall G., Ritz E. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10: 2043- 2048, 1995

4. Amgen Inc. Cinacalcet (Sensipar) US prescribing information [online]. Available from URL: <http://www.sensipar.com> [Accessed 2004 May 5]

5. Attie M.F., Gill J.R.Jr., Stock J.L., Spiegel A.M., Downs R.W.Jr., Levine M.A. et al. Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest 1983;72 (2):667-76.

6. Barman Balfour J.A., Scott L.J. Cinacalcet Hydrochloride; Drugs 2005;65 (2); 271-281

7. Baczynski R., Massry S.G., Kohan R., Magott M., Saglikes Y., Brautbar N. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27: 718-725, 1985

8. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998

9. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., Hercz G., Cunningham J., Abu-Alfa A.K., Messa P., Coyne D.W., Locatelli F., Cohen R.M., Evenepoel P., Moe S.M., Fournier A., Braun J., McCary L.C., Zani V.J., Olson K.A., Drueke T.B., Goodman W.G. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004

10. Bogin E., Massry S.G., Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 67: 1215-1227, 1981

11. Brookman J., Farrow S., Nicholson L., O'Riordan J., and Hendy G. Regulation by calcium of parathyroid hormone mRNA in cultured parathyroid tissue. J Bone Miner Res 1: 529-537, 1986.

12. Brown E.M. (1999). Physiology and pathophysiology of the extracellular calcium-sensing receptor. American Journal of Medicine,106: 238-253.

13. Brown E.M. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens (1993) 2:541-551.

14. Brown E.M., Hebert S.C. Calcium-receptor-regulated parathyroid and renal function. Bone 1997;20 (4):303-9.

15. Brown E.M. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 1991 ;71 (2):371-411.

16. Brown E.M., Gamba G., Riccardi D., Lombardi M., Butters R., Kifor O., Sun A., Hediger M.A., Lytton J., and Hebert S.C. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993.

17. Chin J., Miller S.C., Wada M., Nagano N., Nemeth E.F. & Fox J. (2000). Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. Journal of the American Society of Nephrology, 11: 903-911

18. Chou Y.H., Pollak M.R., Brandi M.L., Toss G., Arnqvist H., Atkinson A.B., Papapoulos S.E., Marx S., Brown E.M., and Seidman J.G. Mutations in the human Ca2+-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet 56: 1075-1079, 1995.

19. Coburn J.W., Charytan C., Chonchol M., et al. Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis [abstract # SA-P0740]. J Am Soc Nedrol 2003; 14 suppl.: 460A

20. Cole D.E.C., Peltekova V.D., Rubin L.A., Hawker G.A., Vieth R., Liew C.C. A 986S polymorphism of the calcium sensing receptor and circulating calcium concentration. Lancet 1999; 353:112-15;

21. Collins M.T., Skarulis M.C., Bilezikian J.P., Silverberg S.J., Spiegel A.M. & Marx S.J. (1998). Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. Journal of Clinical Endocrinology and Metabolism, 83: 1083-1088

22. Colloton M., Shatzen E., Miller G., et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int (2005) 67:467-476.

23. Conigrave A.D., Poronnik P., Delbridge L., Young J.A., and Cook D.I. An inwardly rectifying K+ channel in human adenomatous parathyroid cells. Cell Calcium 14: 517-523, 1993.

24. Cunningham J., Urena P., Reichel H., et al. Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD): abstract SP210, ERA-EDTA 2005. Nephrol Dial Transplant (2005) 20(Suppl 5):V89.

25. Delmez J.A., Kelber J., Noamgenood K.Y., Giles K.S., and Slatopolsky E. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clin Nephrol 54: 301-308, 2000.

26. Doroszewicz J., Waldegger P., Jeck N., Seyberth H., Waldegger S. pH dependence of extracellular calcium sensing receptor activity determined by a novel technique. Kidney Int 2005;67 (1):187-92

27. Edward M. Brown and R. John MacLeod Extracellular Calcium Sensing and Extracellular Calcium Signaling Physiological Reviews, Vol. 81, No. 1, January 2001, pp. 239-297

28. Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., Collins A.J. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005

29. Fox J., Lowe S.H., Conklin R.L., Nemeth E.F. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine (1999) 10:97-103.

30. Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., and Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443, 1993

31. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131- 2138, 2001

32. Garrett J.E., Capuano I.V., Hammerland L.G., Hung B.C., Brown E.M., Hebert S.C., et al. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995;270 (21):12919-25.

33. Giachelli C.M., Jono S., Shioi A., Nishizawa Y., Mori K., Morii H. Vascular calcification and inorganic phosphate. Am J Kidney Dis 38: S34 -S37, 2001

34. Giachelli C.M. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14[Suppl 4]: S300 -S304, 2003

35. Goodman W.G. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59: 1187-1201, 2001.

36. Goodman W.G. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nefrol 2003 dec; 18 (12):1206-10

37. Goodman W.G., Goldin G., Kuizon B.D. et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng G Med 2000; 342: 1478-83

38. Goodman W.G., Frazao J.M., Goodkin D.A., Turner S.A., Liu W. & Coburn J.W. (2000). A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney International, 58: 436-445

39. Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., Barri Y.M., Cohen R.M., and Coburn J.W. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017-1024, 2002.

40. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., Bhatnagar P.K., Lago A.M., Callahan J.F., DelMar E.G., Miller M.A., Nemeth E.F. & Fox J. (2000). Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. Journal of Clinical Investigation, 105: 1595-1604

41. Hammerland L.G., Garrett J.E., Hung B.C.P., Levinthal C., Nemeth E.F. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998;53 (6):1083-8.

42. Hauache O.M., Hu J., Ray K., Xie R., Jacobson K.A. & Spiegel A.M. (2000). Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology, 141: 4156-4163

43. Hauache O.M. Extracellular calcium-sensing receptor: Structural and functional features and association with diseases. Braz J Med Biol Res 2001;34 (5):577-84.

44. Hebert S.C. Extracellular calcium-sensing receptor: Implications for calcium and magnesium handling in the kidney. Kidney Int 1996;50 (6):2129-39

45. Hebert S.C., Brown E.M., Harris H.W. Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 1997;200(Pt 2):295-302

46. Hedback G., Oden A. Increased risk of death from primary hyperparathyroidism-An update. Eur J Clin Invest 28: 271-276, 1998

47. Hofer A.M., Brown E.M. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4: 530-538, 2003

48. Jensen B., Farach-Carson M.C., Kenaley E., Akanbi K.A. High extracellular calcium attenuates adipogenesis in 3T3-L1 preadipocytes. Exp Cell Res 301: 280-292, 2004

49. Kanazirska M.P., Vassilev P.M., Ye C.P., Francis J.E., and Brown E.M. Intracellular Ca2+-activated K+ channels modulated by variations in extracellular Ca2+ in dispersed bovine parathyroid cells. Endocrinology 136: 2238-2243, 1995

50. Kawata T., Imanishi Y., Kobayashi K., et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol (2005) 153:587-594.

51. Kifor O., Moore F.D.J.R., Wang P., Goldstein M., Vassilev P., Kifor I., Hebert S.C., and Brown E.M. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598-1606, 1996.

52. Levi R., Ben-Dov I.Z., Lavi-Moshayoff V., et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with post-translational modification of the trans acting factor AUF1. J Am Soc Nephrol (2006) 17:107-112.

53. Lindberg J.S., Moe S.M., Goodman W.G., Coburn J.W., Sprague S.M., Liu W., Blaisdell P.W., Brenner R.M., Turner S.A., and Martin K.J. The calcimimetic AMG073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248-254, 2003.

54. Lopez-Barneo J., and Armstrong C.M. Depolarizing response of rat parathyroid cells to divalent cations. J Gen Physiol 82: 269-294, 1983.

55. Malluche H.H., Monier-Faugere M.C., Wang G., et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialisis patients with secondary hyperparathyroidism (HPT) [abstract # M016]. 41-st Congress of The European Renal Association and The European Dialisis And Transplant Association; 2004 May 15-18; Lisbon

56. Martin-Salvago M., Villar-Rodriguez J.L., Palma-Alvarez A., Beato-Moreno A., and Galera-Davidson H. Decreased expression of calcium receptor in parathyroid tissue in patients with hyperparathyroidism secondary to chronic renal failure. Endocr Pathol 14: 61-70, 2003.

57. Martin D., Miller G., Colloton M., Shatzen E., and Lacey D. Cinacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic renal insufficiency (CRI) (Abstract). J Am Soc Nephrol 14: 462A., 2003.

58. Moallem E., Kilav R., Silver J., and Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273: 5253-5259, 1998.

59. Moe S.M., Cunningham J., Bommer J., et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant (2005) 20:2186-2193

60. Moe S.M., Chen N.X. Pathophysiology of vascular calcification in chronic kidney disease Circ Res 95: 560-567, 2004

61. Muff R., Nemeth E.F., Haller-Brem S., and Fischer J.A. Regulation of hormone secretion and cytosolic Ca2+ by extracellular Ca2+ in parathyroid cells and C-cells: role of voltage-sensitive Ca2+ channels. Arch Biochem Biophys 265: 128-135, 1988.

62. Nagano N., Nemeth E.F. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: The extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 2005;97 (3):355-60.

63. National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney disease 2003.

64. Nemeth E.F. and Scarpa A. Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor. J Biol Chem 262: 5188-5196, 1987.

65. Nemeth E.F., Steffey M.E., Hammerland L.G., Hung B.C., Van Wagenen B.C., DelMar E.G., and Balandrin M.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045, 1998.

66. Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., and Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635, 2004.

67. Nemeth E.F., Steffey M.E. & Fox J. (1996). The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Pediatric Nephrology, 10: 275-279

68. Nemeth E.F. Ca2+ receptor-dependent regulation of cellular functions. News Physiol Sci 10: 1-5, 1995.

69. Nemeth E.F. Calcium receptors as novel drug targets. In: Principles of Bone Biology (1st ed.), edited by Bilezikian J.P., Raisz L.G., and Rodan G.A. San Diego, CA: Academic, 1996, p. 1019-1035.

70. Odenwald T.R.E., Roesch F., Schaefer F., Schmitt C.P. The calcimimetic R568 lowers blood pressure, but not total body sodium content, in rats [Abstract]. J Am Soc Nephrol 15: 279a, 2004

71. Ohanian J., Gatfield K.M., Ward D.T., Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 288: H1756 -H1762, 2005

72. Owda A.K., Mousa D., Abdallah A.H., Hawas F.A., Al-Harbi W., Fedail H., At-Shoail G., Al-Sulaiman M.H., and Al-Khader A.A. Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment. Ren Fail 24: 165-173, 2002.

73. Pearce S. Extracellular 'calcistat' in health and disease Lancet 1999; 353:83-4,

74. Peacock M., Bilezikian J.P., Preston S., et al. Cinacalcet HCl maintains long-term normocalcemia in patients with primary hyperparathyroidism [e-pub ahead of print]. J Clin Endo 2004 Nov 2

75. Peacock M., Scumpia S., Bolognese M.A., et al. Long-term control of primary hyperparathyroidism with cinacalcet HCl (AMG 073) [abstract#1060] J Bone Miner Res 2003: 18 suppl. 2: S17

76. Pollak M.R., Brown E.M., Chou Y.H.W., Hebert S.C., Marx S.J., Steinman B., Levi T., Seidman C.E., and Seidman J.G. Mutations of the human Ca2+-sensing receptor gene causing familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993.

77. Pollak M.R., Brown E.M., Estep H.L., McLaine P.N., Kifor O., Park J., Hebert S.C., Seidman C.E., and Seidman J.G. Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nat Genet 8: 303-307, 1994.

78. Pollak M.R., Chou Y.H., Marx S.J., Steinmann B., Cole D.E., Brandi M.L., Papapoulos S.E., Menko F.H., Hendy G.N., and Brown E.M. familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 93: 1108-1112, 1994.

79. Raine A.E., Margreiter R., Brunner F.P., Ehrich J.H., Geerlings W., Landais P., Loirat C., Mallick N.P., Selwood N.H., Tufveson G., et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7[Suppl 2]: 7-35, 1992 1

80. Reichel H., Deibert B., Schmidt-Gayk H., Ritz E. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.

81. Rodriguez M., Caravaca F., Fernandez E., Borrego M.J., Lorenzo V., Cubero J., Martin-Malo A., Betriu A., Jimenez A., Torres A., and Felsenfeld A.J. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 56: 306-317, 1999.

82. Russell J., Bar A., Sheamgenood L.M., and Huamgenitz S. Interaction between calcium and 1,25-dihydroxyvitamin D3 in the regulation of preproparathyroid hormone and vitamin D receptor messenger ribonucleic acid in avian parathyroids. Endocrinology 132: 2639-2644, 1993. 394

83. Russell J., Lettieri D.F., and Sheamgenood L.M. Direct regulation by calcium of cytoplasmic messenger ribonucleic acid coding for preproparathyroid hormone in isolated bovine parathyroid cells. J Clin Invest 72: 1851-1855, 1983.

84. Serra A.L., Savoca R., Huber A.R., Hepp U., Delsignore A., Hersberger M., Wüthrich R.P. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients: Nephrol Dial Transplant. 2007 Feb;22 (2):577-83

85. Shane E. Clinical review 122: Parathyroid Carcinoma. J Clin Endocrin Metab 2001; 86 (2): 485-93

86. Silver J., Moallem E., Kilav R., Epstein E., Sela A., and Naveh-Many T. New insights into the regulation of parathyroid hormone synthesis and secretion in chronic renal failure. Nephrol Dial Transplant 11: 2-5, 1996.

87. Silverberg S.J., Bone H.G. III, Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., Kaatz S., Sanguinetti E.L., and Bilezikian J.P. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337: 1506-1510, 1997.

88. Silverberg S.J., Fairman C., Bilezikian J.P., et al. The effects of cinacalcet HCl (AMG073) on serum alcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTx [abstract#SA-420] J Bone Miner Res 2003; 18 suppl. 2: s171

89. Smogorzewski M., Perna A.F., Borum P.R., Massry S.G. Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF. Kidney Int 34: 797-803, 1988 16

90. Stefenelli T., Abela C., Frank H., Koller-Strametz J., Globits S., Bergler-Klein J., Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 82: 106-112, 1997

91. Strippoli G.F., Palmer S., Tong A., Elder G., Messa P., Craig J.C. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis. 2006 May;47 (5):715-26.]

92. Torres P.U. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease J Ren Nutr. 2006 Jul;16 (3):253-8.]

93. Wada M., Furuya Y., Kobayashi N., Kobayashi N., Miyata S., Ishii H., and Nagano N. The calcimimetic compound AMG 073 (cinacalcet HCl) Ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol 14: 48A (abstract SU-FC218), 2003.

94. Wada M., Furuya Y., Sakiyama J., Kobayashi N., Miyata S., Ishii H., and Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977-2983, 1997.

95. Wada M., Ishii H., Furuya Y., Fox J., Nemeth E.F., Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int (1998) 53:448-453.

96. Wada M., Nagano N., Furuya Y., Chin J., Nemeth E.F., and Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57: 50-58, 2000.

97. Wada M., Nagano N., Nemeth E.F. The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens 8: 429-433, 1999

98. Watts. R. W. E. Idiopathic urinary stone disease: possible polygenic aetiological factors. QJM 2005 98 (4):241-246; doi:10.1093/ 041).

99. Quarles L.D., Sherrard D.J., Adler S., Rosansky S.J., Mc-Cary L.C., Liu W., Turner S.A., and Bushinsky D.A. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14: 1710-1721, 2003.

100. Quarles L.D., Spiegel D. M., Qurzi M. et al. The effects of 1-year treatment with the calcimimetic AMG073 and bone health in ESRD patients with secondary hyperparathyroidism (SHPT) [abstract # SU-P0510. J Am Soc Nefrol 2002; 13 suppl.:572A

101. Quinn S.J., Kifor O., Trivedi S., Diaz R., Vassilev P., Brown E. Sodium and ionic strength sensing by the calcium receptor. J Biol Chem 1998;273 (31):19579-86.

102. Yamamoto M., Igarishi T., Muramatsu M., Fukagawa M., Motokura T., and Ogata E. Hypocalcemia increases and hypercalcemia decreases the steady state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 83: 1053-1056, 1989.

103. Yano S., Sugimoto T., Tsukamoto T., Chihara K., Kobayashi A., Kitazawa S., Maeda S., and Kitazawa R. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol 148: 403-411, 2003.

104. Хори Б., Дрюке Т. Взаимосвязь паращитовидных желез и костной ткани в условиях уремии: новое понимание старой проблемы. В книге: "Cовременные аспекты заместительной терапии при почечной недостаточности". Cборник материалов международного нефрологического симпозиума. 8-9 сентября 1998 г., Москва, Россия, стр. 32-37.

105. Amgen Inc Eureopean Comision approves innovative first-in-class treatment for serious complications of chronic kidney disease [online]. Available from URL: http://www.amgen. com [Accessed 2004 Nov 1]


Для цитирования:


., ., . КАЛЬЦИМИМЕТИКИ - НОВЫЙ КЛАСС ПРЕПАРАТОВ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПАРАТИРЕОЗА. Остеопороз и остеопатии. 2008;11(2):29-37. https://doi.org/10.14341/osteo2008229-37

For citation:


ROSTOMYaN L.G., ROZhINSKAYa L.Y., EGShATYaN L.M. KAL'TsIMIMETIKI - NOVYY KLASS PREPARATOV DLYa LEChENIYa GIPERPARATIREOZA. Osteoporosis and Bone Diseases. 2008;11(2):29-37. (In Russ.) https://doi.org/10.14341/osteo2008229-37

Просмотров: 110


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)